Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries

We are analyzing https://link.springer.com/article/10.1007/s00125-012-2582-5.

Title:
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe βˆ’/βˆ’ mice | Diabetologia
Description:
Aims/hypothesis Inhibitors of dipeptidyl peptidase-IV (DPP-IV), such as sitagliptin, increase glucagon-like peptide-1 (GLP-1) concentrations and are current treatment options for patients with type 2 diabetes mellitus. As patients with diabetes exhibit a high risk of developing severe atherosclerosis, we investigated the effect of sitagliptin on atherogenesis in Apoe βˆ’/βˆ’ mice. Methods Apoe βˆ’/βˆ’ mice were fed a high-fat diet and treated with either sitagliptin or placebo for 12 weeks. Plaque size and plaque composition were analysed using Oil Red O staining and immunohistochemistry. Furthermore, in vitro experiments with the modified Boyden chamber and with gelatine zymography were performed to analyse the effects of GLP-1 on isolated human monocyte migration and metalloproteinase-9 (MMP-9) release. Results Treatment of Apoe βˆ’/βˆ’ mice with sitagliptin significantly reduced plaque macrophage infiltration (the aortic root and aortic arch both showing a 67% decrease; p < 0.05) and plaque MMP-9 levels (aortic root showing a 69% and aortic arch a 58% reduction; both p < 0.01) compared with controls. Moreover, sitagliptin significantly increased plaque collagen content more than twofold (aortic root showing an increase of 58% and aortic arch an increase of 73%; both p < 0.05) compared with controls but did not change overall lesion size (8.1 ± 3.5% vs 5.1 ± 2.5% for sitagliptin vs controls; p = NS). In vitro, pretreatment of isolated human monocytes with GLP-1 significantly decreased cell migration induced by both monocyte chemotactic protein-1 and by the protein known as regulated on activation, normal T cell expressed and secreted (RANTES) in a concentration-dependent manner. Furthermore, GLP-1 significantly decreased MMP-9 release from isolated human monocyte-derived macrophages. Conclusions/interpretation Sitagliptin reduces plaque inflammation and increases plaque stability, potentially by GLP-1-mediated inhibition of chemokine-induced monocyte migration and macrophage MMP-9 release. The effects observed may provide potential mechanisms for how DPP-IV inhibitors could modulate vascular disease in high-risk patients with type 2 diabetes mellitus.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Social Networks
  • Science

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We're unsure if the website is profiting.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {πŸ”}

glp, plaque, sitagliptin, article, mice, content, aortic, pubmed, google, scholar, dppiv, cas, diabetes, effects, mmp, macrophage, lesions, treatment, patients, type, migration, collagen, human, levels, root, arch, controls, size, monocyte, cell, cells, study, apoe, inhibition, fig, lesion, germany, highfat, diet, monocytes, glucose, shown, data, reduces, inhibitors, dipeptidyl, peptide, atherosclerosis, activity, glucagonlike,

Topics {βœ’οΈ}

3Β mg h-gly-pro-p-nitroaniline dpp-iv inhibitors des-fluoro-sitagliptin cd26/dipeptidyl-peptidase iv glucose/kg body weight drugs inhibit dpp-iv reduced monocyte/macrophage infiltration dpp-iv activity measurement inhibiting dpp-iv activity western blot analysis dpp-iv inhibitors influence class-matched igg served polyvinylpyrrolidone-free polycarbonate membrane chemokine-induced monocyte migration dpp-iv enzymatic activity plaque monocyte/macrophage content glucose-dependent insulinotropic polypeptide pi3k/akt-dependent pathways dpp-iv substrates include ddp-iv inhibitor treatment random high-power fields apolipoprotein e-deficient mice dpp-iv inhibitor treatment dpp-iv-inhibitor treatment cd8alpha-negative dendritic cells p-myosin light chain human monocyte-derived macrophages primary anti-mac3 antibody goat anti-macrophage-3 antigen des-fluoro-sitagliptin dipeptidyl peptidase-iv dipeptidyl peptidase activity dipeptidyl peptidase-4 inhibitor cell type-specific marker pancreatic beta cells enhancing insulin secretion macrophages reduces atherosclerosis chemokine-induced migration dyslipidemia inhibits toll research diets d12108 plaque macrophage content dpp iv/cd26 plaque macrophage infiltration dpp-iv activity influence vascular chemokine privacy choices/manage cookies dpp-iv inhibitors dpp-iv inhibitor low collagen content monocyte-derived macrophages macrophage mmp-9 production

Questions {❓}

  • Geelhoed-Duijvestijn PH (2007) Incretins: a new treatment option for type 2 diabetes?

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe βˆ’/βˆ’ mice
         description:Inhibitors of dipeptidyl peptidase-IV (DPP-IV), such as sitagliptin, increase glucagon-like peptide-1 (GLP-1) concentrations and are current treatment options for patients with type 2 diabetes mellitus. As patients with diabetes exhibit a high risk of developing severe atherosclerosis, we investigated the effect of sitagliptin on atherogenesis in Apoe βˆ’/βˆ’ mice. Apoe βˆ’/βˆ’ mice were fed a high-fat diet and treated with either sitagliptin or placebo for 12Β weeks. Plaque size and plaque composition were analysed using Oil Red O staining and immunohistochemistry. Furthermore, in vitro experiments with the modified Boyden chamber and with gelatine zymography were performed to analyse the effects of GLP-1 on isolated human monocyte migration and metalloproteinase-9 (MMP-9) release. Treatment of Apoe βˆ’/βˆ’ mice with sitagliptin significantly reduced plaque macrophage infiltration (the aortic root and aortic arch both showing a 67% decrease; p &lt; 0.05) and plaque MMP-9 levels (aortic root showing a 69% and aortic arch a 58% reduction; both p &lt; 0.01) compared with controls. Moreover, sitagliptin significantly increased plaque collagen content more than twofold (aortic root showing an increase of 58% and aortic arch an increase of 73%; both p &lt; 0.05) compared with controls but did not change overall lesion size (8.1 ± 3.5% vs 5.1 ± 2.5% for sitagliptin vs controls; p = NS). In vitro, pretreatment of isolated human monocytes with GLP-1 significantly decreased cell migration induced by both monocyte chemotactic protein-1 and by the protein known as regulated on activation, normal T cell expressed and secreted (RANTES) in a concentration-dependent manner. Furthermore, GLP-1 significantly decreased MMP-9 release from isolated human monocyte-derived macrophages. Sitagliptin reduces plaque inflammation and increases plaque stability, potentially by GLP-1-mediated inhibition of chemokine-induced monocyte migration and macrophage MMP-9 release. The effects observed may provide potential mechanisms for how DPP-IV inhibitors could modulate vascular disease in high-risk patients with type 2 diabetes mellitus.
         datePublished:2012-05-18T00:00:00Z
         dateModified:2012-05-18T00:00:00Z
         pageStart:2267
         pageEnd:2275
         sameAs:https://doi.org/10.1007/s00125-012-2582-5
         keywords:
            Atherosclerosis
            Glucagon-like peptide-1
            Incretins
            Plaque stability
            Type 2 diabetes
            Internal Medicine
            Metabolic Diseases
            Human Physiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig5_HTML.gif
         isPartOf:
            name:Diabetologia
            issn:
               1432-0428
               0012-186X
            volumeNumber:55
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:F. Vittone
               affiliation:
                     name:University of Ulm
                     address:
                        name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                        type:PostalAddress
                     type:Organization
                     name:University of Ulm
                     address:
                        name:Department of Internal Medicine I – Endocrinology, University of Ulm, Ulm, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Liberman
               affiliation:
                     name:University Hospital Aachen
                     address:
                        name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. Vasic
               affiliation:
                     name:University of Ulm
                     address:
                        name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Ostertag
               affiliation:
                     name:University of Ulm
                     address:
                        name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Esser
               affiliation:
                     name:University Hospital Aachen
                     address:
                        name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. Walcher
               affiliation:
                     name:University of Ulm
                     address:
                        name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Ludwig
               affiliation:
                     name:Department of Pharmacology of the RWTH Aachen
                     address:
                        name:Department of Pharmacology of the RWTH Aachen, Aachen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Marx
               affiliation:
                     name:University Hospital Aachen
                     address:
                        name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:M. Burgmaier
               affiliation:
                     name:University Hospital Aachen
                     address:
                        name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe βˆ’/βˆ’ mice
      description:Inhibitors of dipeptidyl peptidase-IV (DPP-IV), such as sitagliptin, increase glucagon-like peptide-1 (GLP-1) concentrations and are current treatment options for patients with type 2 diabetes mellitus. As patients with diabetes exhibit a high risk of developing severe atherosclerosis, we investigated the effect of sitagliptin on atherogenesis in Apoe βˆ’/βˆ’ mice. Apoe βˆ’/βˆ’ mice were fed a high-fat diet and treated with either sitagliptin or placebo for 12Β weeks. Plaque size and plaque composition were analysed using Oil Red O staining and immunohistochemistry. Furthermore, in vitro experiments with the modified Boyden chamber and with gelatine zymography were performed to analyse the effects of GLP-1 on isolated human monocyte migration and metalloproteinase-9 (MMP-9) release. Treatment of Apoe βˆ’/βˆ’ mice with sitagliptin significantly reduced plaque macrophage infiltration (the aortic root and aortic arch both showing a 67% decrease; p &lt; 0.05) and plaque MMP-9 levels (aortic root showing a 69% and aortic arch a 58% reduction; both p &lt; 0.01) compared with controls. Moreover, sitagliptin significantly increased plaque collagen content more than twofold (aortic root showing an increase of 58% and aortic arch an increase of 73%; both p &lt; 0.05) compared with controls but did not change overall lesion size (8.1 ± 3.5% vs 5.1 ± 2.5% for sitagliptin vs controls; p = NS). In vitro, pretreatment of isolated human monocytes with GLP-1 significantly decreased cell migration induced by both monocyte chemotactic protein-1 and by the protein known as regulated on activation, normal T cell expressed and secreted (RANTES) in a concentration-dependent manner. Furthermore, GLP-1 significantly decreased MMP-9 release from isolated human monocyte-derived macrophages. Sitagliptin reduces plaque inflammation and increases plaque stability, potentially by GLP-1-mediated inhibition of chemokine-induced monocyte migration and macrophage MMP-9 release. The effects observed may provide potential mechanisms for how DPP-IV inhibitors could modulate vascular disease in high-risk patients with type 2 diabetes mellitus.
      datePublished:2012-05-18T00:00:00Z
      dateModified:2012-05-18T00:00:00Z
      pageStart:2267
      pageEnd:2275
      sameAs:https://doi.org/10.1007/s00125-012-2582-5
      keywords:
         Atherosclerosis
         Glucagon-like peptide-1
         Incretins
         Plaque stability
         Type 2 diabetes
         Internal Medicine
         Metabolic Diseases
         Human Physiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2582-5/MediaObjects/125_2012_2582_Fig5_HTML.gif
      isPartOf:
         name:Diabetologia
         issn:
            1432-0428
            0012-186X
         volumeNumber:55
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:F. Vittone
            affiliation:
                  name:University of Ulm
                  address:
                     name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                     type:PostalAddress
                  type:Organization
                  name:University of Ulm
                  address:
                     name:Department of Internal Medicine I – Endocrinology, University of Ulm, Ulm, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Liberman
            affiliation:
                  name:University Hospital Aachen
                  address:
                     name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Vasic
            affiliation:
                  name:University of Ulm
                  address:
                     name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Ostertag
            affiliation:
                  name:University of Ulm
                  address:
                     name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Esser
            affiliation:
                  name:University Hospital Aachen
                  address:
                     name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Walcher
            affiliation:
                  name:University of Ulm
                  address:
                     name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Ludwig
            affiliation:
                  name:Department of Pharmacology of the RWTH Aachen
                  address:
                     name:Department of Pharmacology of the RWTH Aachen, Aachen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Marx
            affiliation:
                  name:University Hospital Aachen
                  address:
                     name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:M. Burgmaier
            affiliation:
                  name:University Hospital Aachen
                  address:
                     name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Diabetologia
      issn:
         1432-0428
         0012-186X
      volumeNumber:55
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Ulm
      address:
         name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
         type:PostalAddress
      name:University of Ulm
      address:
         name:Department of Internal Medicine I – Endocrinology, University of Ulm, Ulm, Germany
         type:PostalAddress
      name:University Hospital Aachen
      address:
         name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
         type:PostalAddress
      name:University of Ulm
      address:
         name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
         type:PostalAddress
      name:University of Ulm
      address:
         name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
         type:PostalAddress
      name:University Hospital Aachen
      address:
         name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
         type:PostalAddress
      name:University of Ulm
      address:
         name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
         type:PostalAddress
      name:Department of Pharmacology of the RWTH Aachen
      address:
         name:Department of Pharmacology of the RWTH Aachen, Aachen, Germany
         type:PostalAddress
      name:University Hospital Aachen
      address:
         name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
         type:PostalAddress
      name:University Hospital Aachen
      address:
         name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:F. Vittone
      affiliation:
            name:University of Ulm
            address:
               name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
               type:PostalAddress
            type:Organization
            name:University of Ulm
            address:
               name:Department of Internal Medicine I – Endocrinology, University of Ulm, Ulm, Germany
               type:PostalAddress
            type:Organization
      name:A. Liberman
      affiliation:
            name:University Hospital Aachen
            address:
               name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
               type:PostalAddress
            type:Organization
      name:D. Vasic
      affiliation:
            name:University of Ulm
            address:
               name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
               type:PostalAddress
            type:Organization
      name:R. Ostertag
      affiliation:
            name:University of Ulm
            address:
               name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
               type:PostalAddress
            type:Organization
      name:M. Esser
      affiliation:
            name:University Hospital Aachen
            address:
               name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
               type:PostalAddress
            type:Organization
      name:D. Walcher
      affiliation:
            name:University of Ulm
            address:
               name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
               type:PostalAddress
            type:Organization
      name:A. Ludwig
      affiliation:
            name:Department of Pharmacology of the RWTH Aachen
            address:
               name:Department of Pharmacology of the RWTH Aachen, Aachen, Germany
               type:PostalAddress
            type:Organization
      name:N. Marx
      affiliation:
            name:University Hospital Aachen
            address:
               name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:M. Burgmaier
      affiliation:
            name:University Hospital Aachen
            address:
               name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
      name:Department of Internal Medicine I – Endocrinology, University of Ulm, Ulm, Germany
      name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
      name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
      name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
      name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
      name:Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany
      name:Department of Pharmacology of the RWTH Aachen, Aachen, Germany
      name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
      name:Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany

External Links {πŸ”—}(155)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

4.12s.